BIM-23190

发表于由

BIM-23190;

BIM-23190 是 somatostatin 的类似物，是 SSTR2 和 SSTR5 的选择性激动剂，对SSTR2 和SSTR5 的Ki 值分别为 0.34 nM 和 11.1 nM。BIM-23190 可用于糖尿病和癌症研究。

BIM-23190amp;;

BIM-23190 Chemical Structure

CAS No. : 182153-96-4

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3].

体外研究
(In Vitro)

BIM-23190 tends to mildly stimulate PRL secretion[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

BIM-23190 (50 μg/mouse, twice a day) exhibits significant anti-tumor (C6 glioma) activity[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male athymic nude (nu/nu) mice, 5-6 wk old (C6 glioma)[2].
Dosage: 50 μg/mouse
Administration: Injected twice a day for 19 days.
Result: Significantly reduced the tumor growth rate.

分子量

1202.45

Formula

C57H79N13O12S2
CAS 号

182153-96-4
Sequence

{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-Cys-Tyr-{D-Trp}-Lys-{Abu}-Cys-Thr-NH2 (Disulfide bridge: Cys2-Cys7)
Sequence Shortening

{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-CY-{D-Trp}-K-{Abu}-CT-NH2 (Disulfide bridge: Cys2-Cys7)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.

    [2]. Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.

    [3]. T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.